The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
June 15th 2025
Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.
Managing and Monitoring Cardiotoxic Risks During Cancer Treatment
September 30th 2024Aaron Adkisson, PharmD, discusses the importance of considering factors such as age, gender, and cardiovascular comorbidities when monitoring and managing cardiotoxic risks in patients with cancer. also emphasizing patient education on recognizing early heart failure symptoms.
Read More
Factors to Consider When Selecting T Cell-Directed Therapies for Myeloma
September 26th 2024Rahul Banerjee, MD, FACP, discussed his presentation at the International Myeloma Society 2024 Annual Meeting on available T cell-directed therapies for myeloma treatment, including CAR T-cell therapies and bispecific antibodies.
Watch
Study: Most Pregnancies Following alloHCT Were Spontaneous and Had Favorable Outcomes
September 25th 2024About 72% of the observed pregnancies after allogeneic hematopoietic cell transplantation occurred spontaneously, whereas remaining pregnancies were a result of assisted reproductive activities.
Read More
Dato-DXd Did Not Achieve Statistically Significant OS in Patients With Breast Cancer
September 24th 2024Compared with chemotherapy, datopotamab deruxtecan (Dato-DXd) did not achieve a statistically significant overall survival (OS) in patients with inoperable or metastatic HR+/HER2-low or negative breast cancer.
Read More